Prostate cancer remains the second leading cause of cancer death among men in the U.S., with nearly 30,000 deaths annually. Deaths from prostate cancer have declined by about 40% since the advent of PSA screening in the late 1980s, and 40-70% of that decline may be attributable to screening. However, radiation therapy and surgery have a negative impact on quality of life.
Patterns of care in prostate cancer (PCa) have changed dramatically in the past 20 years, changing the way patients with this tumor present and how they are evaluated before and after diagnosis. Advances have been made in PCa imaging, biopsy methodology, in understanding causative factors and disease, in treatment-related quality of life, and in predicting the behavior of individual tumors using risk strata. Despite these advances, no consensus has emerged regarding the optimal treatment for the most common patient with PCa.
This two-day must-attend conference will cover the latest advancements in prostate cancer screening, detection and treatment, including:
Cleveland Clinic’s Glickman Urological and Kidney Institute is recognized worldwide for excellence in patient care, teaching and research.
The Glickman Urological and Kidney Institute merges Cleveland Clinic’s urology and nephrology programs. This consolidation of disciplines allows us to better serve patients in the prevention, diagnosis and treatment of kidney disease while we continue to provide high-quality patient care and carry on innovative research in all aspects of urology.
Urology and nephrology physicians and scientists at Cleveland Clinic are recognized worldwide for excellence in patient care, teaching and research. This year, U.S. News & World Report ranked both the urology program and our kidney disease program No. 2 in the nation.
“Prostate cancer is the second leading cause of cancer death in American men. One in seven men will be diagnosed with prostate cancer and 233,000 new cases are diagnosed annually”
The conference is ideally suited for physicians, nurses, administrators and other health professionals involved in prostate cancer – representing Community Hospitals, Health Systems, Academic Medical Centers, Hospital Networks, Medical Laboratories, and Research Institutions, including:
At Boston Scientific, we help you meet the challenges of constant change by delivering innovations across five urology subspecialties. With more than 40-years of experience, we are the global leader in the treatment of erectile dysfunction and male incontinence. Join us as we evolve the future of urology.
At Janssen Oncology, we’re shaping the future of cancer treatment. And in the process, we’re striving to change expectations of what a cancer diagnosis means. Our purpose is driven by an urgency and commitment to bringing transformational cancer solutions to the people who need them. Passionate about our work, we are driven by the personal connection many of us share with the disease. With our partners, we focus on delivering solutions that make a positive impact on human health. We are part of Janssen Biotech, Inc., and the Janssen Pharmaceutical Companies of Johnson & Johnson.
Bayer HealthCare is one of the world’s leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Medical Care, and Pharmaceuticals divisions. As a specialty pharmaceutical company, Bayer HealthCare provides products for General Medicine, Hematology, Neurology, Oncology and Women’s Healthcare.
TOLMAR is deeply committed to its partnership with the urology community. Passion fueled the innovation, development, and advancement of ELIGARD® (leuprolide acetate for injectable suspension). TOLMAR is the inventor, developer, and manufacturer of all of the products in the ELIGARD family.
Applied Radiology is a board-reviewed clinical journal reaching radiology professionals worldwide in print and digital formats since 1972. Editorially, Applied Radiology covers all aspects of diagnostic radiology, interventional techniques and therapeutic specialties.
AuntMinnie features the latest news and information about medical imaging and is a comprehensive community website for radiologists and related professionals in the medical imaging industry.
AuntMinnie provides a forum for radiologists, business managers, technologists, members of organized medicine, and industry to meet, transact, research, and collaborate on topics within the field of radiology with the ease and speed that only the Internet can provide.
Cancer Network is an online resource that offers a wide range of news, information, and educational content geared toward oncology professionals. It is also home of the journal ONCOLOGY, which provides review articles and other features written by experts in the field that focus on practical issues in oncology. Cancer Network and ONCOLOGY are published by UBM Medica, one of the largest healthcare media and publishing companies in the U.S., serving the information needs of decision makers who cover the patient care spectrum.
As “The Trusted Resource for Emerging Technology and Clinical Applications in Medical Imaging and Radiation Oncology,” Imaging Technology News (ITN) showcases the latest, most innovative diagnostic & therapeutic technologies and service solutions. ITN is edited for professionals in radiology/medical imaging, therapeutic radiology, business administration and IT in hospitals, freestanding imaging and radiation oncology centers and purchasing organizations. Features include Comparison Charts, Technology Overviews, Advances In, Business & Economics, Case Studies and more.
Men’s Health Network (MHN) is a national non-profit organization whose mission is to reach men and their families where they live, work, play, and pray with health prevention messages and tools, screening programs, educational materials, advocacy opportunities, and patient navigation. MHN is committed to improving the health and well-being of men and their families. The goals of the Network are as follows: